bioRxivImmunology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, D. R. Martinez, K. W. Bock, M. Minai, B. M. Nagata, G. B. Hutchinson, K. Bahl, D. Garcia-Dominguez, L. Ma, I. Renzi, W.-P. Kong, , Wang
Abstract
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
- organism: mouse
- assay: multiome
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
- Immunogenicity and Protective Efficacy of a SARS-CoV-2 mRNA Vaccine Encoding Secreted Non-Stabilized Spike Protein in Mice
E. Prompetchara, C. Ketloy, … K. Ruxrungtham·bioRxiv·Sep 7, 2022
- Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains
G. Stewart-Jones, S. M. Elbashir, … A. Carfi·bioRxiv·Oct 7, 2022
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates
R. Alimohammadi, M. Porgoo, … M. Azizi·bioRxiv·Mar 5, 2022
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
K. S. Corbett, M. C. Nason, … Leung·bioRxiv·Apr 20, 2021
- Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
K. V. Kalnin, T. Plitnik, … D. Casimiro·bioRxiv·Oct 14, 2020